Redeye briefly comments on ExpreS2ion’s announcement of a published Hong Kong patent application covering glyco-engineering methods within the ExpreS2 platform. While early-stage and not value-defining in isolation, the filing strengthens the company’s platform IP with potentially broad application across multiple vaccine and immunotherapy programs and supports long-term partnering opportunities, particularly in Asia.
LÄS MER
